Clinical experience of SIB-IMRT in anal cancer and selective literature review

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Janssen, Stefan ^a   Glanzmann, Christoph ^a   Bauerfeind, Peter ^a   Stieb, Sonja ^a   Studer, Gabriela ^a   Brown, Michelle ^a   Riesterer, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anal cancer; Definitive radio chemotherapy; SIB IMRT

Indexed keywords

ADULT; ANUS CANCER; ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; DOUBLE BLIND PROCEDURE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROCTITIS; RADIATION DOSE; SIMULTANEOUSLY INTEGRATED BOOST INTENSITY MODULATED RADIATION THERAPY; SINGLE BLIND PROCEDURE; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; AGED; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; MIDDLE AGED; MORTALITY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84907261919     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-199     Document Type: Article

References (19)

1. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004, 101(2):281-288. 10.1002/cncr.20364, 15241824.
2. Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974, 17(3):354-356. 10.1007/BF02586980, 4830803.
3. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15(5):2040-2049.
4. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996, 348(9034):1049-1054.
5. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB3, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008, 299(16):1914-1921. 10.1001/jama.299.16.1914, 18430910.
6. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005, 63(2):354-361. 10.1016/j.ijrobp.2005.02.030, 16168830.
7. Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA, Chang DT. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011, 117(15):3342-3351. 10.1002/cncr.25901, 21287530.
8. Salama JK, Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw SL, Chmura SJ. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007, 25(29):4581-4586. 10.1200/JCO.2007.12.0170, 17925552.
9. Chuong MD, Freilich JM, Hoffe SE, Fulp W, Weber JM, Almhanna K, Dinwoodie W, Rao N, Meredith KL, Shridhar R. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res 2013, 6(2):39-45. 3674462, 23745158.
10. Menkarios C, Azria D, Laliberté B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Aillères N, Fenoglietto P. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2007, 2:41. 10.1186/1748-717X-2-41, 2204019, 18005443.
11. Brooks CJ, Lee YK, Aitken K, Hansen VN, Tait DM, Hawkins MA. Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (R Coll Radiol) 2013, 25(3):155-161. 10.1016/j.clon.2012.08.008, 22981970.
12. Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, Crane CH, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol 2013,
13. Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012, 82(1):153-158. 10.1016/j.ijrobp.2010.09.030, 21095071.
14. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol 2013, 14(6):516-524. 10.1016/S1470-2045(13)70086-X, 23578724.
15. Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, Haddock MG, Rotman M, Parikh PJ, Safran H, Willett CG. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013, 86(1):27-33. 10.1016/j.ijrobp.2012.09.023, 3619011, 23154075.
16. Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Glanzmann C, Ciernik IF. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 2007, 6(3):218-226. 10.1016/j.brachy.2007.02.152, 17681244.
17. Graf R, Wust P, Hildebrandt B, Gögler H, Ullrich R, Herrmann R, Riess H, Felix R. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 2003, 65(1):14-22. 10.1159/000071200, 12837978.
18. Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol*Biol*Phys 1997, 39(3):651-657.
19. Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. Int J Radiat Oncol Biol Phys 2013, 85(5):e201-e207. 10.1016/j.ijrobp.2012.12.008, 23517808.